Post hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney disease
Kam Wa Chan, J. David Smeijer, Meir Schechter, Niels Jongs, Priya Vart, Donald E. Kohan, Ron T. Gansevoort, Adrian Liew, Sydney C.W. Tang, Christoph Wanner, Dick de Zeeuw, Hiddo J L Heerspink*
Research output: Contribution to journal › Journal article › peer-review
7Citations
(Scopus)
Fingerprint
Dive into the research topics of 'Post hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney disease'. Together they form a unique fingerprint.